ADC Therapeutics Company

ADC Therapeutics is a biotechnology company that specializes in the development of highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. They use the latest-generation pyrrolobenzodiazepine (PBD) dimer technology to develop their ADCs, which have a superior therapeutic index compared to first-generation PBD ADCs. The company has specialized capabilities unique to the lifecycle of ADCs, including research, translational and chemistry, manufacturing, and controls. ADC Therapeutics is a commercial-stage biotechnology company that aims to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates.

Invests into

Headquarters: Lausanne
Employee Number: 251-500
Industry: PharmTech
Estimated Revenue: $69.8 millionADC